Try our Advanced Search for more refined results
Life Sciences
-
April 06, 2026
WilmerHale Adds Regulatory Atty From Mayer Brown In DC
WilmerHale announced Monday it has hired a veteran U.S. Food and Drug Administration and life sciences regulatory attorney from Mayer Brown LLP.
-
April 06, 2026
Catching Up With Delaware's Chancery Court
The Delaware Chancery Court's docket this past week featured a mix of high-profile corporate disputes, insider trading allegations, contract fights and significant rulings shaping fiduciary duty and deal litigation.
-
April 06, 2026
Cooley, Wilson Sonsini Steer Neurocrine's $2.9B Soleno Buy
Neurocrine Biosciences has agreed to acquire biotechnology company Soleno Therapeutics for about $2.9 billion in cash, in a deal advised by Cooley LLP and Wilson Sonsini Goodrich & Rosati PC, the companies said on Monday.
-
April 03, 2026
Case-By-Case Guide As Justices Eye Landmark Pharma Law
Drugmakers and prominent allies are inundating the U.S. Supreme Court with calls to scrutinize Medicare's new power to slash payments by tens of billions of dollars, and the justices look poised to take up or turn down a fistful of legal challenges in one fell swoop.
-
April 03, 2026
Barnes & Thornburg Snags PFAS Expert From Venable
Barnes & Thornburg LLP is beefing up its product liability and mass torts practice with the addition of a Venable LLP partner known for representing and counseling companies in environmental and toxic tort-related matters, including issues involving so-called forever chemicals, the firm announced Thursday.
-
April 03, 2026
SEC Moves To Set Up $40M Investor Fund In Cassava Case
The U.S. Securities and Exchange Commission asked a Texas federal court on Friday to establish a $40 million fund to potentially compensate investors harmed by a Texas biopharmaceutical company and two former executives' alleged misstatements about an Alzheimer's drug, following the company's 2024 settlement with the regulator.
-
April 03, 2026
Legislative Update: Cannabis And Psychedelics Bill Roundup
State lawmakers in Delaware and West Virginia advanced legislation to more tightly regulate kratom products, Missouri and Kentucky legislators considered bills to fund research into the therapeutic uses of the psychedelic ibogaine, and Idaho's Legislature came together to urge voters to reject a medical marijuana legalization proposal that could be on the ballot this November. Here are the major moves in cannabis and psychedelics legislation from the past week.
-
April 03, 2026
EPA Eyes Microplastics, Drugs For Drinking Water Watch List
The U.S. Environmental Protection Agency is looking to include microplastics and pharmaceuticals in its drinking water contaminants list for the first time, the agency has announced in a move it says could make the proposed contaminants a consideration in regulatory action.
-
April 03, 2026
Law360 Announces The Members Of Its 2026 Editorial Boards
Law360 is pleased to announce the formation of its 2026 Editorial Advisory Boards.
-
April 03, 2026
Aetna Escapes COVID Testing Payment Suit In Calif.
A Nebraska testing laboratory failed to prove that Aetna underpaid more than $53 million for COVID-19 testing services, a California federal judge has ruled, dismissing the lab's federal racketeering and state law claims against the insurer but leaving the door open to an amended suit.
-
April 03, 2026
NYC Fights Sanctions Over Discovery In IVF Sex Bias Dispute
New York City urged a federal judge to reject a gay couple's sanctions bid in their suit claiming a municipal health plan blocked them from receiving in vitro fertilization coverage out of discrimination, calling their concerns with the city's sluggish discovery production in the case premature.
-
April 03, 2026
Caterpillar Worker's Bankruptcy Dooms Genetic Privacy Claim
An Illinois federal judge has thrown out a Caterpillar Inc. employee's proposed class genetic privacy suit over allegedly illegal medical history probes, saying the worker's midcase Chapter 7 bankruptcy filing means the claims now belong to his bankruptcy estate and not to him personally.
-
April 02, 2026
Georgia Midwifery Laws Violate State Constitution, Suit Says
A trio of midwives are challenging Georgia laws that restrict their ability to practice, arguing that the statutes exacerbate an ongoing maternal health crisis and conflict with the Peach State's constitution.
-
April 02, 2026
Squires Gives Go-Ahead To 5 Patent Reviews, Denies 8
In the latest order summarizing his decisions on requests for America Invents Act patent reviews, U.S. Patent and Trademark Office Director John Squires has granted five petitions and turned down eight others.
-
April 02, 2026
Petition To Repeal Legal Pot Mobilizes A Showdown In Mass.
A campaign to repeal the legalization of retail cannabis in Massachusetts via ballot initiative — the first campaign of its kind in the country — is uniting legalization advocates, entrepreneurs and industry players in a coordinated response to defeat the effort before it spreads to other states.
-
April 02, 2026
Ex-Pharma Exec Hit With $5.3M Fee Award In Del.
The Delaware Chancery Court has ordered a former pharmaceutical executive to pay more than $5.3 million in attorney fees following years of litigation over alleged disloyal conduct and trade secret misuse, concluding that the award is reasonable despite objections that the amount was excessive.
-
April 02, 2026
Alexion Beats Trade Secret Claims In Amyndas Suit
Amyndas Pharmaceuticals failed to specifically identify the trade secrets it claimed pharmaceutical company Alexion learned of during early partnership talks and improperly used to launch a business collaboration with another competitor, a Massachusetts federal judge has found.
-
April 02, 2026
Trump Orders 100% Pharma Tariff, Modifies Metals Duties
Later this year, the U.S. will impose 100% tariffs on imported pharmaceuticals, but drug companies could qualify for reduced tariff rates as low as zero if they agree to invest domestically and enter most-favored-nation drug-pricing agreements with the government, according to an executive order President Donald Trump signed Thursday.
-
April 02, 2026
Snell & Wilmer Names Life Sciences Pro As San Diego Leader
Snell & Wilmer LLP has tapped a longtime corporate attorney who specializes in the life sciences industry to be the new head of its San Diego office.
-
April 02, 2026
Teva $35M Delayed Generic Inhalers Deal Gets Initial OK
A Massachusetts federal judge Thursday granted initial approval to a $35 million deal that Teva Pharmaceuticals agreed to pay to resolve claims from a coalition of union healthcare funds that say the company schemed to delay generic competition for its QVAR asthma inhalers.
-
April 02, 2026
Vape Sellers, Makers Evade Ga. Woman's RICO Scheme Suit
A Georgia federal judge has tossed a suit against numerous vape sellers and makers alleging they conspired to sell vapes with illegal levels of delta-9 THC, saying her complaint fails to allege any kind of scheme, but rather amounts to describing the normal supply chain.
-
April 01, 2026
Ex-Wilson Sonsini M&A Co-Head Rejoins Goodwin In SF
A former partner at Goodwin Procter LLP's Silicon Valley office has rejoined the firm in San Francisco after co-leading Wilson Sonsini Goodrich & Rosati PC's mergers and acquisitions practice for five years, Goodwin announced on Wednesday.
-
April 01, 2026
7th Circ. Says Ill. BIPA Amendment Applies Retroactively
The Seventh Circuit held Wednesday that a liability-limiting amendment to Illinois' biometric privacy law applies to every lawsuit pending at the time the amendment took effect, ruling that the amendment is only a procedural change to the law and, therefore, must be applied retroactively.
-
April 01, 2026
Berkshire Must Defend Trulieve In Worker Death Suit
An insurance company that is a unit of Berkshire Hathaway had an obligation to defend Trulieve Inc. against a Massachusetts wrongful death lawsuit brought by the family of a cannabis worker, a Florida federal judge has ruled, rejecting arguments that the worker wasn't an employee.
-
April 01, 2026
3 Federal Circuit Clashes To Watch In April
The Federal Circuit argument calendar for this month includes Centripetal Networks' appeal of a decision clearing Cisco of infringing cybersecurity patents after a multibillion-dollar award was thrown out, as well as Ecobee's challenge to an $11.5 million infringement verdict involving smart thermostats.
Expert Analysis
-
Series
Volunteering With Scouts Makes Me A Better Lawyer
Serving as an assistant scoutmaster for my son’s troop reaffirmed several skills and principles crucial to lawyering — from the importance of disconnecting to the value of morality, says Michael Warren at McManis Faulkner.
-
Series
Law School's Missed Lessons: In Court, It's About Storytelling
Law school provides doctrine, cases and hypotheticals, but when lawyers step into the courtroom, they must learn the importance of clarity, credibility, memorability and preparation — in other words, how to tell simple, effective stories, say Nicholas Steverson and Danielle Trujillo at Wheeler Trigg, and Lisa DeCaro at Courtroom Performance.
-
Pros And Cons Of FDA's Push For Nonprescription Drugs
The U.S. Food and Drug Administration's recent moves to shift more prescription drugs to over-the-counter status could increase access to important medications, but also bring potential safety risks and other trade-offs for drug companies, say attorneys at Hogan Lovells.
-
How Recent Del. Rulings Clarify M&A Deal Fraud Carveouts
Two recent Delaware decisions have provided clarity regarding when a party can or cannot rely on representations made during the course of an M&A transaction, particularly on the scope and enforceability of antireliance provisions, and on representations they knew or should have known were false, says Anthony Boccamazzo at Olshan Frome.
-
High Court's 'Skinny Label' Case May Tackle Wider Questions
The U.S. Supreme Court's upcoming decision in Hikma v. Amarin will have important ramifications for broader debates over what defines a generic version of a drug, and the pending case is already altering patent practice, say attorneys at Taft.
-
Aligning Microsoft Tools With NYC Bar AI Recording Guidance
The New York City Bar Association’s recently issued formal opinion, providing ethical guidance on artificial intelligence-assisted recording, transcription and summarization, raises immediate questions about data governance and e-discovery for companies that use Microsoft 365 and Copilot, say Staci Kaliner, Martin Tully and John Collins at Redgrave.
-
FDA's Biosimilarity Guidance Holds Uncertain Implications
The U.S. Food and Drug Administration's new draft guidance aimed at simplifying the biosimilarity demonstration process may not be enough to overcome the barriers that have historically constrained biosimilar competition, and could affect biosimilar access in unexpected ways, say analysts at Analysis Group.
-
Unpacking Key Themes From NY's New Healthcare Strategy
New York Gov. Kathy Hochul's 2026 State of the State agenda, read together with the state's fiscal year 2027 executive budget, reflect a clear framework to utilize Medicaid as the state's operating platform for healthcare reform, say attorneys at Sheppard.
-
5 Different AI Systems Raise Distinct Privilege Issues
A New York federal court’s recent U.S. v. Heppner decision, holding that a defendant’s use of Claude was not privileged, only addressed one narrow artificial intelligence system, but lawyers must recognize that the spectrum of AI tools raises different confidentiality and privilege questions, says Heidi Nadel at HP.
-
Opinion
AI-Assisted Arbitration Needs Safeguards To Ensure Fairness
As tribunals and arbitral institutions increasingly use artificial intelligence tools in their decision-making processes, clear disclosure standards and procedural safeguards are necessary to ensure that efficiency gains do not erode the fairness principles on which arbitration depends, says Alexander Lima at Wesco International.
-
Trans Care Enforcement Landscape Is Evolving Quickly
The recent coordinated federal effort to reshape pediatric gender-affirming care through enforcement and funding pressure has created a rapidly evolving regulatory environment marked by shifting risk assessments and potential downstream market effects for healthcare institutions and life sciences companies, say attorneys at Arnall Golden.
-
Series
Playing Piano Makes Me A Better Lawyer
Playing piano and practicing law share many parallels relating to managing complexity: Just as hearing an entire musical passage in my head allows me to reliably deliver the message, thinking about the audience's impression helps me create a legal narrative that keeps the reader engaged, says Michael Shepherd at Fish & Richardson.
-
3 Cases Highlight SEC Distinction Between Exec, Co. Liability
Three recent enforcement actions against Spero Therapeutics, Lottery.com and Archer-Daniels-Midland demonstrate that while public companies are subject to liability for misrepresentations, the U.S. Securities and Exchange Commission is focused on individual liability when disclosure violations involve so-called half-truths, say attorneys at Cooley.
-
AI-Generated Doc Ruling Guides Attys On Privilege Risks
A New York federal court's ruling, in U.S. v. Heppner, that documents created by a defendant using an artificial intelligence tool were not privileged, can serve as a guide to attorneys for retaining attorney-client or work-product privilege over client documents created with AI, say attorneys at Sher Tremonte.
-
The Law Firm Merger Diaries: Leadership Strategy After Day 1
For law firm leaders, ensuring a newly combined law firm lives up to its promise, both in its first days of operation and well after, includes tough decisions, clear and specific communication, and cheerleading, says Peter Michaud at Ballard Spahr.